^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) + AZD1208 (PIM inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3ß Activation and GSK-3ß-Mediated Proteasomal Degradation of c-Myc
Published date:
11/04/2021
Excerpt:
Ba/F3-ITD and MV4-11 cells, with FLT3-ITD, and FLT3-ITD AML patient blasts were cultured with the pan-Pim inhibitor AZD1208 (1 μM) and/or the FLT3 inhibitors gilteritinib or quizartinib...Treatment with Pim inhibitor AZD1208 and FLT3 inhibitor gilteritinib or quizartinib combination…Concurrent treatment of cells with FLT3-ITD with Pim kinase inhibitor enhances the efficacy of FLT3 inhibitors.
DOI:
10.1182/blood-2021-151737
